BMS reports detailed survival data for failed Opdivo maintenance trial in SCLC

Bristol-Myers said Opdivo nivolumab plus Yervoy ipilimumab as maintenance therapy of extensive-stage disease small cell lung cancer following first-line platinum-based chemotherapy led to a median overall survival of 9.2 months vs. 9.6 months for placebo (HR=0.92, 95% CI: 0.75, 1.12, p=0.3693) in the Phase III CheckMate -451 trial.

Bristol-Myers Squibb Co. (NYSE:BMY) reported last year that the PD-1 inhibitor Opdivo plus anti-CTLA-4 mAb Yervoy missed the OS primary endpoint, but did not disclose details...